Zarxio pi. Zarxio (filgrastimsndz) [prescribing information].

Zarxio pi © 2025 Sandoz Group AG Mar 8, 2016 · The FDA has approved a supplemental Biologics License Application (sBLA) for Zarxio (filgrastim-sndz; Sandoz) to update the Warnings and Precautions section of the drug label. HIGHLIGHTS OF PRESCRIBING INFORMATION These highlights do not include all the information needed to use LEQEMBI™ safely and effectively. Author Janet Colwell. • Nypozi and Neupogen also share the following indication: — Increase survival in patients acutely exposed to myelosuppressive doses of radiation HIGHLIGHTS OF PRESCRIBING INFORMATION These highlights do not include all the information needed to use ZARXIO safely and effectively. • Similar to Neupogen, Zarxio and Nivestym, Releuko is contraindicated in patients with a history of serious allergic reactions to human granulocyte colony-stimulating factors such as filgrastim products or pegfilgrastim products. , indication(s), dosing regimen(s)), strength(s), dosage form(s), and route(s) of administration described in its Full Prescribing Information. What side effects may I notice from receiving this medication? Side effects that you should report to your care team as soon as possible: Allergic reactions—skin rash, itching, hives, swelling of the face, lips, tongue, or throat HIGHLIGHTS OF PRESCRIBING INFORMATION These highlights do not include all the information needed to use ZARXIO safely and effectively. Updates These highlights do not include all the information needed to use ZARXIO safely and effectively. Zarxio injections can be given by your doctor as an IV infusion or a subcutaneous injection (under the skin). A ruptured spleen can cause death. Quoted prices are for cash-paying customers and are not valid with insurance plans. 9,10 The results of these clinical trials are summarized in the prescribing information for filgrastim-sndz. Jan 18, 2009 · • Zarxio is not recommended in patients requiring direct administration of less than 0. • Sep 16, 2024 · Note: This document provides detailed information about Zarxio Side Effects associated with filgrastim. ZARXIO (filgrastim-sndz) is biosimilar* to NEUPOGEN (filgrastim). 4/30/2017 These highlights do not include all the information needed to use ZARXIO safely and effectively. ; 2021. Your spleen may become enlarged and can rupture. ZARXIO (FILGRASTIM-SNDZ) IS BIOSIMILAR* TO NEUPOGEN (FILGRASTIM). Nov 17, 2016 · Since the manufacturer did not provide the evidence for interchangeable approval, Zarxio is not interchangeable with Neupogen. See full prescribing information for LEQEMBI™. Prior to use‚ take the carton out of the refrigerator and place the sealed blister tray on a clean flat surface for a minimum of 30 minutes to allow the product to reach room temperature. intravenous infusion. BSC Drug Coverage Criteria to Determine Medical Necessity Reviewed by P&T Committee Contraindication. 1). ZARXIO® (fi… Mar 6, 2015 · Neupogen or Zarxio were administered subcutaneously at 5 mcg/kg body weight starting on day 2 of cycle 1 and given until the absolute neutrophil count (ANC) recovered to 10 Gi/L after the nadir or HIGHLIGHTS OF PRESCRIBING INFORMATION These highlights do not include all the information needed to use NEULASTA safely and effectively. Talk to your healthcare Oct 25, 2024 · The recommended dosage of ZARXIO is 10 mcg/kg as a single daily subcutaneous injection for patients exposed to myelosuppressive doses of radiation. PMID Go to Homepage. 1 Recommended Dosage Filgrastim-sndz (Zarxio®) and Filgrastim-aafi (Nivestym®) are FDA indicated for the following: • Decrease the incidence of infection‚ as manifested by febrile neutropenia‚ in patients with nonmyeloid malignancies receiving myelosuppressive anticancer drugs associated Discover VENCLEXTA® (venetoclax tablets): An oral therapy to help you fight certain blood cancers. gov route(s) of administration) described in its Full Prescribing Information. 2. 17 days for Zarxio and 1. S. Neupogen (filgrastim) [prescribing information]. YUFLYMA (adalimumab -aaty) is biosimilar * to HUMIRA (adalimumab ). • Patients with cancer undergoing bone marrow transplantation. indication(s), dosing regimen(s)), strength(s), dosage form(s), and route(s) of administration described in its Full Prescribing Information. Zarzio is used to stimulate the production of white blood cells in the following situations: to reduce the duration of neutropenia (low levels of neutrophils, a type of white blood cell) and the occurrence of febrile neutropenia (neutropenia with fever) in patients receiving chemotherapy (cancer treatment) that is cytotoxic (cell-killing); May 2, 2023 · Zarxio (filgrastim-sndz) Granix (tbo-filgrastim) Nivestym (filgrastim-aafi) Myelosuppressive Chemotherapy Treatment. Recommended starting dose is 5 mcg/kg/day subcutaneous injection, short intravenous infusion (15 to 30 minutes), or continuous Oct 25, 2024 · ZARXIO is indicated to reduce the duration of neutropenia and neutropenia-related clinical sequelae‚ e. Amgen; 2021. Pharmacology, adverse reactions, warnings, and ZARXIOside effects. ZARXIO הוא תרופה המעודדת את צמיחת הנויטרופילים ומציעה תוכניות סיוע למטופלים. CareFirst Prior Authorization Request For Neutropenia "I had severe neutropenia (count dropped to 0) and was given an injection of Zarxio for five consecutive days in the hospital. GRANIX® (tbo-filgrastim) injection, for subcutaneous use Initial U. See Full Prescribing Information for recommended dosage adjustments and timing of administration. 1158/2159-8290. It effectively jolted the bone marrow back to working properly; blood counts have remained in the normal range for the eight months since my treatment. Related treatment guides. Infasurf ® (calfactant) Intratracheal Suspension Prescribing Information, ONY, Inc, March 2018. ZARXIO (filgrastim-sndz) injection, for subcutaneous or intravenous use Initial U. See full prescribing information for ZARXIO. Nivestym, Zarxio, Neulasta, Fulphila, Udenyca) or using more than one G-CSF drug during a single chemotherapy cycle for neutropenia prophylaxis due to myelosuppressive chemotherapy Coverage for a Non-FDA approved indication, requires that criteria outlined in Health and Safety Sep 30, 2024 · Neupogen, Zarxio, and Nivestym can be used in a procedure called leukapheresis, where white blood cells needed for a stem cell transplant are removed from the body. Adult and pediatric dosage. 6. CD-ND2015-002. Amjevita offers significant cost savings, with a list price 55% Prescribing information states that Zarxio should be administered once a day via a subcutaneous injection, intravenous injection, or intravenous infusion. Last updated on Oct 15, 2023. o 10 mcg/kg/day given as an intravenous infusion no longer than 24 hours. Jan 1, 2025 · 1. See Full Prescribing Information for recommended dosage adjustments infusion. ZARXIO™ (filgrastim-sndz) injection, for subcutaneous or intravenous use Initial U. HIGHLIGHTS OF PRESCRIBING INFORMATION . 5) 03/2016 ZARXIO is a leukocyte growth factor indicated to: In patients with cancer receiving ZARXIO as an adjunct to myelosuppressive chemotherapy‚ to avoid the potential risks of excessive leukocytosis‚ it is recommended that ZARXIO therapy be discontinued if the ANC surpasses 10‚000/mm 3 after the chemotherapy-induced ANC nadir has occurred. Size: 300 mcg syringe 10 × 0. doi: 10. APPROVAL: 2018 . Approval:2023 . Learn how to administer ZARXIO, a medication that stimulates white blood cell growth and offers patient assistance programs. 2 Administration 2 3 DOSAGE FORMS AND STRENGTHS 3 Sep 30, 2024 · Neupogen, Zarxio, and Nivestym can be used in a procedure called leukapheresis, where white blood cells needed for a stem cell transplant are removed from the body. Mar 6, 2015 · In patients with cancer receiving ZARXIO as an adjunct to myelosuppressive chemotherapy, to avoid the potential risks of excessive leukocytosis, it is recommended that ZARXIO therapy be discontinued if the ANC surpasses 10,000/mm 3 after the chemotherapy-induced ANC nadir has occurred. 5 milliliters, depending on the pharmacy you visit. 100% of reviewers reported a positive effect, while 0% reported a negative effect. Applies to filgrastim: injection solution. NEULASTA® (pegfilgrastim) injection, for subcutaneous use Initial U. See full prescribing information for FULPHILA. 4 mL (150 mg/mL) in each single-dose prefilled These highlights do not include all the information needed to use cartridge. FULL PRESCRIBING INFORMATION: CONTENTS * 1 INDICATIONS AND USAGE Biosimilarity of ZIEXTENZO has been demonstrated for the condition(s) of use (e. HIGHLIGHTS OF PRESCRIBING INFORMATION These highlights do not include all the information needed to use ZARXIO safely and effectively. 67% of reviewers reported a positive effect, while 0% reported a negative effect. com discount card which is accepted at most U. 23 The safety profile of Zarxio as compared to Neupogen was not markedly different. pharmacies. com. 1) Patients with cancer undergoing bone marrow transplantation o 10 mcg/kg/day given as an intravenous infusion no longer than 24 hours. This page cannot be displayed because your browser has been configured to disable JavaScript, also known as "Active Scripting". Jun 1, 2018 · Class: Biological Therapy Generic Name: Filgrastim-sndz Trade Name: Zarxio™ For which conditions is Zarxio approved for? Zarxio is approved to decrease the incidence of infection in patients with a low neutrophil (type of white blood cell that helps fight infection) count due to cancer treatment, a condition called neutropenia. Find medical information for Zarxio (filgrastim-sndz) on epocrates online, including its dosing, contraindications, drug interactions, and pill pictures. These highlights do not include all the information needed to use UDENYCA safely and effectively. Includes: indications, dosage, adverse reactions and pharmacology. UDENYCA (pegfilgrastim-cbqv) is biosimilar* to NEULASTA HIGHLIGHTS OF PRESCRIBING INFORMATION • Injection: 360 mg/2. Nov 10, 2024 · Biosimilarity of ZARXIO has been demonstrated for the condition(s) of use (e. Review this drug In patients with cancer receiving ZARXIO as an adjunct to myelosuppressive chemotherapy, to avoid the potential risks of excessive leukocytosis, it is recommended that ZARXIO therapy be discontinued if the ANC surpasses 10,000/mm 3 after the chemotherapy-induced ANC nadir has occurred. Zarxio (filgrastim-sndz) is a leukocyte growth factor biosimilar to the reference product Neupogen, indicated for the treatment of neutropenia associated with chemotherapy. Approval: 2015 RECENT MAJOR CHANGES -----­ See Full Prescribing Information for recommended dosage adjustments and timing of administration. 2 * Study duration: 24 weeks HIGHLIGHTS OF PRESCRIBING INFORMATION These highlights do not include all the information needed to use GRANIX safely and effectively. See Full Prescribing Information for recommended dosage Zarxio has an average rating of 8. Jan 27, 2021 · Brand name: Zarxio Generic name: filgrastim-sndz Dosage form: Injection Company: Sandoz Inc. See full prescribing information for YUFLYMA. 1 Patients with Cancer Receiving Myelosuppressive Chemotherapy 2 2. © 2025 Sandoz Group AG These highlights do not include all the information needed to use ZARXIO safely and effectively. 14(b)] in hours. Pegfilgrastim use in myeloid malignancies or MDS, except for members with AML/ALL in Mar 25, 2024 · 2. Monitor CBCs at least twice weekly during therapy. ZARXIO ® (filgrastim-sndz) injection, for subcutaneous or intravenous use Initial U. MOZOBIL (plerixafor) Injection, Solution for subcutaneous use Initial U. Zarxio is a biosimilar to its reference product Neupogen (J1442). Something went wrong: t. ZARXIO (filgrastim-sndz) is biosimilar* to NEUPOGEN (filgrastim). G. More about Neupogen () More about Zarxio () Ratings & Reviews: Neupogen has an average rating of 10. full prescribing information 1 INDICATIONS AND USAGE NYVEPRIA is indicated to decrease the incidence of infection, as manifested by febrile neutropenia, in patients with non-myeloid malignancies receiving myelosuppressive anti-cancer drugs associated with a clinically significant incidence of febrile neutropenia [see Clinical Studies (14) ] . CONTENT OF LABELING As soon as possible, but no later than 14 days from the date of this letter, submit, via the FDA automated drug registration and listing system (eLIST), the content of labeling [21 601. These highlights do not include all the information needed to use ZARXIO safely and effectively. ‚ febrile neutropenia, in patients with nonmyeloid malignancies undergoing myeloablative chemotherapy followed by bone marrow transplantation [see Clinical Studies ]. Epub 2015 Mar 19. See full Prescribing and Safety information. converted from Zarxio to Nivestym in June 2022, and from Truxima to Riabni in July 2022. Read the Full Prescribing Information, Instructions for Use, and Medication Guide that comes with Zarxio. FULPHILA ® (pegfilgrastim-jmdb) injection, for subcutaneous use Initial U. See full prescribing information for GRANIX. See full prescribing information for MOZOBIL. NEUPOGEN ® is contraindicated in patients with a history of serious allergic reactions to human granulocyte colony-stimulating factors (G-CSFs), such as filgrastim or pegfilgrastim More about Neulasta (pegfilgrastim) More about Zarxio () Ratings & Reviews: Neulasta has an average rating of 5. Filgrastim-sndz (ZARXIO) National Drug Monograph September 2016 VA Pharmacy Benefits Management Services, Medical Advisory Panel, and VISN Pharmacist Executives The purpose of VA PBM Services drug monographs is to provide a focused drug review for making formulary decisions. • This year, Kaiser Permanente has switched almost 90% of our commercial and Medicare members from Humira, a biologic used to treat rheumatoid arthritis, to the new biosimilar Amjevita. © 2025 Sandoz Group AG Zarxio, Nivestym, or Granix should be used in these circumstances). Neupogen, Granix, Zarxio, Nivestym, Releuko. at 1-800-525-8747 or FDA at 1-800-FDA-1088 or www. Uses; Before taking patients receiving chemotherapy with a high risk of neutropenia, Zarxio was non-inferior to Neupogen on the primary endpoint of duration of severe neutropenia (1. 5 mL ZARXIO is indicated to reduce the duration of neutropenia and neutropenia-related clinical sequelae‚ e. The NCCN Acute Lymphoblastic Leukemia Clinical Practice Guidelines in Oncology (version 2. Zarxio (filgrastimsndz) [prescribing information]. Treatment for: Neutropenia Associated with Chemotherapy. Revised: 11/2018 FULL PRESCRIBING INFORMATION: CONTENTS** FULL PRESCRIBING INFORMATION 2 1 INDICATIONS AND USAGE 2 2 DOSAGE AND ADMINISTRATION 2 2. Single Chronic Kidney Disease: In controlled trials, patients experienced greater risks for death, serious adverse cardiovascular reactions, and stroke when administered erythropoiesis-stimulating agents (ESAs) to target a hemoglobin level of greater than 11 g/dL (5. Filgrastim-sndz (ZarxioTM) Effective: 4/1/2018 Page 1 of 4 Filgrastim-sndz (ZarxioTM) Place of Service Office Administration Outpatient Facility Administration Infusion Center Administration Home Infusion Administration Self-Administration HCPCS: Q5101/J3490 [Injection, Filgrastim, (G-CSF), Biosimilar, 1 microgram] ZARXIO prescription and dosage information for physicians and health care professionals. 20 days for Neupogen). g. Neupogen, Leukine, Zarxio, Nivestym, or Granix use within 7 days of Pegfilgrastim. Oct 15, 2023 · Generic name: Filgrastim-sndz [ fil-GRA-stim ] Brand name: Zarxio Drug class: Colony stimulating factors Medically reviewed by Drugs. See Full Prescribing Information for recommended dosage adjustments and timing of administration (2. caremark. 4 out of 10 from a total of 71 ratings on Drugs. Approval: 2015 . Sandoz Inc- . 10 The BPCIA legislation states that biosimilar drugs are not How to take Zarxio. Review this drug • Zarxio® (filgrastim-sndz) [Prescribing Information]. F. Approval: 2015 -----INDICATIONS AND USAGE-----ZARXIO is a leukocyte growth factor indicated to: These highlights do not include all the information needed to use ZARXIO safely and effectively. PHARMACY POLICY STATEMENT. , indication(s), dosing regimen(s), strength(s), dosage form(s), and route(s) of administration described in its Full Prescribing Information. See Full Prescribing Information for recommended dosage HIGHLIGHTS OF PRESCRIBING INFORMATION These highlights do not include all the information needed to use ZARXIO. ZARXIO safely and effectively. Other dosage forms: solution; Serious side effects of Zarxio Zarxio® NDC #: 61314-0318-10. 2015 May;5(5):460. 5 mL) injectable solution is around $296 for a supply of 0. This waiver applies to all future supplements containing revised labeling unless we notify you otherwise. LEQEMBI™ (lecanemab-irmb) injection, for intravenous use . Your doctor may let you or a caregiver give subcutaneous injections at home. Rolvedon may cause serious side effects, including: Spleen rupture. 2024 – HIGHLIGHTS OF PRESCRIBING INFORMATION These highlights do not include all the information needed to use MOZOBIL safely and effectively. Approval: 2023 Zarxio package insert / prescribing information for healthcare professionals. 5 mL intravenous infusion. 1) • Patients with cancer undergoing bone marrow transplantation - 10 mcg/kg/day given as an intravenous infusion no longer than 24 hours. ‚ febrile neutropenia, in patients with nonmyeloid malignancies undergoing Your healthcare provider or nurse will show you how to prepare and inject ZARXIO properly using the ZARXIO prefilled syringe with UltraSafe Passive® Needle Guard. 5. Approval: 2008 -----INDICATIONS AND USAGE----- Jan 1, 2025 · GA-MED-P-366579 DCH Approved Template on: 12/23/2020 . Rolvedon is administered subcutaneously via a single-dose prefilled syringe. Side effects The FDA-approved label for Zarxio lists common side effects including fever, pain, rash, cough, and difficulty breathing. 3 out of 10 from a total of 4 ratings on Drugs. CVS Caremark Specialty Pharmacy 2211 Sanders Road NBT-6 Northbrook, IL 60062 Phone: 1-888-877-0518 Fax: 1-855-330-1720 www. YUFLYMA (adalimumab-aaty) injection, for subcutaneous use InitialU. Sep 10, 2024 · Rolvedon side effects. FULL PRESCRIBING INFORMATION: CONTENTS * 1 INDICATIONS AND USAGE See specific instructions in prescribing information for Zarxio, Releuko, Nivestym, or Nypozi prefilled syringes with BD UltraSafe Plus Passive Needle Guard; syringes are not designed to allow for direct administration of doses of . SKYRIZI® (risankizumab-rzaa) injection, for subcutaneous or More about Zarxio Ratings & Reviews: Be the first to share your experience with this drug. fda. infusion. Approval: 2015 -----INDICATIONS AND USAGE-----ZARXIO is a leukocyte growth factor indicated to: • Nypozi, Zarxio, Nivestym and Neupogen also share the following indication: — Mobilize autologous hematopoietic progenitor cells into the peripheral blood for collection by leukapheresis. See full prescribing information for UDENYCA. prescribing information. Initial U. To report SUSPECTED ADVERSE REACTIONS, contact Sandoz Inc. Neupogen, Zarxio, Nivestym: 5 mcg/kg/day SC or IV infusion (short 15-30 min or continuous); may increase by 5 mcg/kg increments according to duration and severity of ANC; Granix: 5 mcg/kg/day SC MR C26683-A Neupogen, Granix, Zarxio, Nivestym, Releuko SGM – 01/2024. Approval: 2015 ZARXIO (filgrastim-sndz) is biosimilar* to NEUPOGEN (filgrastim). 25 Jan 16, 2024 · Preferred No Zarxio Q5101 Injection, filgrastim-sndz, biosimilar, (zarxio), 1 microgram Non-Preferred Yes Neupogen J1442 Injection, filgrastim (g-csf), excludes biosimilars, 1 Go to Homepage. Approval: 2002 -----RECENT MAJOR CHANGES----- Patients With Cancer Receiving Myelosuppressive Chemotherapy. Georgia Medicaid Jan 1, 2025 · 1. SKYRIZI safely and effectively. Mar 1, 2021 · Biosimilarity of ZIEXTENZO has been demonstrated for the condition(s) of use (e. 0. 16 Adverse effects are similar to the reference product and include nausea, fever pain, dyspnea, rash, fatigue, and thrombocytopenia. at is not a function See full list on drugs. subcutaneous or intravenous injection [prescribing information]. (7) Policy Update Date of last revision: 1Q2024 Date of next review: 3Q2024 ; Changes from previous policy version: • No clinical change to policy following revision. See full prescribing information for Intravenous infusion (3) SKYRIZI. Approval: 2012 RECENT MAJOR CHANGES Warnings and Precautions, ZIEXTENZO is a long-acting filgrastim biosimilar that helps protect against infection during chemotherapy. Zarxio is administered via subcutaneous injection or an intravenous infusion for roughly 15 to 30 minutes. NIVESTYM ® is indicated to decrease the incidence of infection‚ as manifested by febrile neutropenia‚ in patients with nonmyeloid malignancies receiving myelosuppressive anti-cancer drugs associated with a significant incidence of severe neutropenia with fever Jan 1, 2025 · 1. Administer ZARXIO as soon as possible after suspected or confirmed exposure to radiation doses greater than 2 gray (Gy). See Full Prescribing Information for recommended dosage adjustments Biosimilarity of ZARXIO has been demonstrated for the condition(s) of use (e. See Full Prescribing Information for recommended dosage Overall, 11 clinical trials were performed in the 1980s and 1990s to demonstrate the efficacy and safety of filgrastim (the reference drug) for its 5 FDA-approved indications. Zarxio has an average rating of 8. 3. UDENYCA ® (pegfilgrastim-cbqv) injection, for subcutaneous use-----INITIAL U. Development timeline Survanta ® (beractant) Intratracheal Suspension Prescribing Information, AbbVie Inc, October 2020. (2. Neutropenia Associated with Chemotherapy; Peripheral Progenitor Cell Transplantation; Bone Marrow Transplantation; Neutropenia Jan 1, 2023 · Zarxio (filgrastim) is an artificial version of a natural substance that is made in your body and is used to aid the production of white blood cells. Zarxio prices Jun 30, 2023 · Zarxio prescribing information; Filgrastim (AHFS Monograph) Other brands. 48% of reviewers reported a positive effect, while 41% reported a negative effect. 2 Administration. Approval: 2018 FULPHILA ® (pegfilgrastim-jmdb) is biosimilar* to NEULASTA ® (pegfilgrastim). 1) Patients with cancer undergoing bone marrow transplantation. 3 mL due to the potential for dosing errors. 2 DOSAGE AND ADMINISTRATION 2. Revised: 08/2019. San Diego, CA: Tanvex, June 2024. Revised: 03/2021 . 0 out of 10 from a total of 3 ratings on Drugs. This Category A Prior Approval sBLA provides for the following changes to align the Zarxio United States Prescribing Information (USPI) with the US-licensed Neupogen USPI, approved on April 18, 2023: More about Zarxio Ratings & Reviews: Be the first to share your experience with this drug. 2 * Study duration: 24 weeks See full prescribing information for complete boxed warning. Patient assistance programs for this medication are offered through Sandoz. These highlights do not include all the information needed to use FULPHILA safely and effectively. (1) patients receiving chemotherapy with a high risk of neutropenia, Zarxio was non-inferior to Neupogen on the primary endpoint of duration of severe neutropenia (1. Some dosage forms listed on this page may not apply specifically to the brand name Zarxio. FDA approves first biosimilar, zarxio Cancer Discov. o Neupogen®, NivestymTM, NypoziTM, ReleukoTM, Zarxio®: To decrease the incidence of infection, as manifested by febrile neutropenia, in patients with non-myeloid malignancies receiving myelosuppressive anti-cancer drugs associated with a significant incidence of HIGHLIGHTS OF PRESCRIBING INFORMATION These highlights do not include all the information needed to use YUFLYMA safely and effectively. View all 3 reviews View all 4 reviews FULL PRESCRIBING INFORMATION OPDUALAG ™ (nivolumab and relatlimab-rmbw) 1 INDICATIONS AND USAGE OPDUALAG™ (nivolumab and relatlimab-rmbw) is indicated for the treatment of adult and pediatric patients 12 years of age or older with unresectable or metastatic melanoma. See full prescribing information for NEULASTA. Warnings and Precautions: Glomerulonephritis (5. com Page 1 of 10. This price guide is based on using the Drugs. PIONEER was a randomized, double-blind, comparative study of efficacy and safety between ZARXIO and NEUPOGEN ® in 218 breast cancer patients treated with myelosuppressive chemotherapy. Neupogen is also used in patients who have been exposed to a certain amount of radiation. " All Drugs; Human Drugs; Animal Drugs o Neupogen, Nivestym, Nypozi, Releuko, Zarxio: To decrease the incidence of infection, as manifested by febrile neutropenia, in patients with nonmyeloid malignancies receiving myelosuppressive anti-cancer drugs associated. • Warnings and precautions of Releuko include fatal splenic rupture, acute respiratory distress Public Health Service Act for Zarxio (filgrastim-sndz) injection. Neupogen, Nivestym, Releuko, Nypozi. com Zarxio® NDC #: 61314-0318-10. Biosimilarity of ZARXIO has been demonstrated for the condition(s) of use (e. gov Go to Homepage. Princeton, NJ: Sandoz Inc; 9/2022. The cost for Zarxio (sndz 300 mcg/0. Zarxio comes as a prefilled syringe. Generic Name: filgrastim-sndz. Amgen; 2021 . The spring-mechanism of the needle guard apparatus affixed to HIGHLIGHTS OF PRESCRIBING INFORMATION These highlights do not include all the information needed to use ZARXIO safely and effectively. 3 mL (180 mcg) LABEL - Food and Drug Administration ZARXIO safely and effectively.